Kumar, Rakesh
GlaxoSmithKline (United States)
2 papers on CoChatORCID 0000-0002-6384-1160
Most cited papers
- Verified
Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity
Atkins, C., Liu, Q., Minthorn, E., Zhang, S.-Y., Figueroa, D. J., Moss, K., Stanley, T. B., Sanders, B., Goetz, A., Gaul, N., et al. (2013) · Cancer Research
Endoplasmic Reticulum Stress and DiseasePI3K/AKT/mTOR signaling in cancer
Cited by 443
- Verified
The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma
Spencer, A., Yoon, S.-S., Harrison, S. J., Morris, S. R., Smith, D. A., Brigandi, R. A., Gauvin, J., Kumar, R., Opalinska, J. B., & Chen, C. (2014) · Blood
Multiple Myeloma Research and TreatmentsPI3K/AKT/mTOR signaling in cancer
Cited by 142
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free